Gupta S. K. et al.: Lenacapavir as part of a Combination Regimen in Treatment-Naïve People with HIV: Week 54 Results

Zurück zur Übersicht

12.-16.02.2022 / CROI

Studiensammlung zu HIV

Avihingsanon A. et al.: Week 48 Results of a Phase 3 Randomized Controlled Trial of B/F/TAF vs DTG + F/TDF as Initial Treatment in Adults with HIV/HBV Coinfection (ALLIANCE)

29.07.-12.08.2022 / AIDS 2022

Boopathy A. V. et al.: Flt3 Agonist Enhances Immunogenicity of Arenavirus-Based Vaccine Vector in Macaques

29.07.-12.08.2022 / AIDS 2022

Cai Y. et al.: Metabolomic and Lipidomic Correlates of Time-to-HIV-Rebound in Viremic Controllers Treated with Vesatolimod

29.07.-12.08.2022 / AIDS 2022

Avihingsanon A. et al.: Pharmacokinetics of a Simplified Subcutaneous Lenacapavir Regimen Versus Phase 2/3 Regimen

29.07.-12.08.2022 / AIDS 2022

Kiweewa M. F. A. et al.: Use of the Recent Infection Testing Algorithm to Estimate Background HIV Incidence in Micro-Epidemic Areas Within Uganda

29.07.-12.08.2022 / AIDS 2022

Kumar P. et al.: Injection-Site Reaction Experience in Clinical Studies of People Using Lenacapavir For HIV Treatment

29.07.-12.08.2022 / AIDS 2022

Margot N. et al.: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment

29.07.-12.08.2022 / AIDS 2022

Mounzer K. et al.: Lipid Parameters and Lipid-Modifying Agent Use in Participants Initiating F/TAF or F/TDF for PrEP in the DISCOVER Trial

29.07.-12.08.2022 / AIDS 2022

Rathbun R. et al.: Real-World HIV Renal Outcomes With TDF to TAF Switch

29.07.-12.08.2022 / AIDS 2022

Robineau O. et al.: Longitudinal Analysis of Weight Change in HIV-1 Treatment-Naïve and -Experienced People Living With HIV (PLWH) Initiating/Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies

29.07.-12.08.2022 / AIDS 2022